Track United Therapeutics Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

United Therapeutics Corporation UTHR Open United Therapeutics Corporation in new tab

564.81 USD
P/E
18.76
EPS
27.87
P/B
3.22
ROE
19.72
Beta
0.86
Target Price
593.92 USD
United Therapeutics Corporation logo

United Therapeutics Corporation

🧾 Earnings Recap – Q3 2025

United Therapeutics Corporation reported a record revenue of $800 million for Q3 2025, reflecting a 7% year-over-year growth, driven by strong demand for Tyvaso and Orenitram and significant advancements in its clinical pipeline.

  • Fully enrolled three Phase III trials, achieving best-ever results for pulmonary fibrosis, indicating strong potential to expand patient treatment.
  • Launched new Tyvaso DPI 80-microgram cartridges to enhance dosing convenience and capture additional market share in the pulmonary hypertension space.
  • Significant progress in securing favorable payer coverage decisions, reinforcing Tyvaso DPI's competitive positioning in the market.
  • Confidently projecting a $4 billion revenue run rate by 2027, backed by ongoing product innovations and market demand.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 6, 2026
P/E18.76
EPS27.87
Book Value162.60
Price to Book3.22
Debt/Equity0.53
% Insiders1.941%
Growth
Revenue Growth0.07%
Earnings Growth0.25%
Estimates
Forward P/E15.95
Forward EPS32.78
Target Mean Price593.92

DCF Valuation

Tweak assumptions to recompute fair value for United Therapeutics Corporation (UTHR)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

United Therapeutics Corporation Logo United Therapeutics Corporation Analysis (UTHR)

United States Health Care Official Website Stock

Is United Therapeutics Corporation a good investment? United Therapeutics Corporation (UTHR) is currently trading at 564.81 USD. Market analysts have a consensus price target of 593.92 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 18.76. This valuation is generally in line with the broader market.

Earnings Schedule: United Therapeutics Corporation is expected to release its next earnings report on May 6, 2026. The market consensus estimate for Forward EPS is 32.78.

Investor FAQ

Does United Therapeutics Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is United Therapeutics Corporation?

United Therapeutics Corporation is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 6, 2026. The company currently has a trailing EPS of 27.87.

Company Profile

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Exchange Ticker
NMS (United States) UTHR
FRA (Germany) UTH.F

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Sept. 23, 2009 2.000000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion